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Atypical  haemolytic-uraemic  syndrome  in a young  patient
with renal,  neurological,  ocular  and  cardiovascular
involvement
Síndrome  hemolítico  urémico  atípico  en  un  paciente  joven  con
compromiso  renal,  neurológico,  ocular  y  cardiovascular
To the Editor,
We  present the case of a 23-year-old man  with a 3-month
history of headache, loss of vision, loss of appetite, and
ocular involvement; ocular damage is not frequently reported
in the literature.1,2
In more  than half of the patients with aHUS, it is possible
to identify the complement mutation or the mutation in otherfoamy urine. In the previous week, he had been bedrid-
den, with sensory disturbances, oliguria, and dyspnoea. Upon molecules leading to abnormal complement regulation. How-
eculizumab, achieving a good response with no further needinitial assessment he appeared generally unwell, drowsy,
disorientated, tachycardic, hypertensive, and tachypnoeic.
He had asterixis, uraemic breath, jugular venous disten-
sion, breath sounds with bibasal rales, and oedema of lower
limbs. Lab test on admission showed elevated nitrogen prod-
ucts, metabolic acidosis with a wide anion gap, evidence
of non-immune microangiopathic haemolytic anaemia and
thrombocytopenia (Table 1). Further tests were requested,
including ADAMTS13 activity, and infection and immune pro-
ﬁles, which were negative (Table 1). Treatment was started
with haemodialysis, parenteral labetalol, red cell transfusion,
and plasma exchange. Once uraemia and hypertensive cri-
sis were controlled, ophthalmological examination revealed
a marked loss of visual acuity (RE: 20/400 + 1; LE: 20/150 − 1)
and hypertensive retinopathy. On day 7, haemolytic activ-
ity was controlled, which allowed discontinuation of plasma
exchanges. However, the patient relapsed 48 h later, plasma
exchanges were restarted and a deﬁnitive diagnosis was made
of aHUS (Fig. 1). Treatment with eculizumab was initiated, and
plasma exchanges were stopped. The patient made adequate
progress, with recovery of vision (20/30 in both eyes), how-
ever, dialysis had to be maintained. Genetic studies to detect
complement mutations associated with aHUS were negative
(Table 1). At 9 month follow-up, the patient remained dialysis-
dependent; therefore, a diagnosis was made of end-stage renal
disease (ESRD) secondary to aHUS, and the workup for renal
transplantation was initiated.
Atypical HUS is an extremely rare chronic genetic disease.
It is caused by an abnormality in the regulation of comple-
ment and can lead to severe sequelae in multiple organs and
even death.1–4 It is characterised by the triad of microan-
giopathic haemolytic anaemia, thrombocytopenia, and renal
failure, though it can affect any organ.1,2 Our patient displayed
renal, haematological, neurological, cardiovascular, and
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of therapy. However genetic studies should be performed to
establish prognosis, as some mutations are more  aggressive
than others. Moreover, genetic study allows more  adequate
strategy for renal transplantion.1,2,5 Up to 30% of patients have
no documented genetic mutation,4,6 as it was the case in our
patient.
The treatment of choice for aHUS is eculizumab, a human-
ised monoclonal antibody that blocks the cleavage of the C5
component of complement, thus preventing the release of
the anaphylatoxin C5a and the formation of the membrane
attack complex C5b-9. This prevents endothelial damage
and the generation of thrombotic microangiopathy.1,7,8 As
a prerequisite for starting eculizumab, the patient must
be vaccinated against meningococcus and start antibiotic
prophylaxis directed against meningococcus whilst the vac-
cine becomes effective. The earlier eculizumab is started in
patients with aHUS, the higher the likelihood of recovery and
the fewer sequelae.5,9 Nonetheless, whilst the diagnosis of
aHUS is being established, plasma exchanges can stabilise
the patient’s haemolytic activity, therefore these should be
started early if the clinical picture is one of a thrombotic
microangiopathy. It should be kept in mind that blood samples
should be obtained for ADAMTS13 activity and autoanti-
body proﬁle prior to plasma exchange to avoid missing other
diagnoses.1,5,7 If the deﬁnitive diagnosis is aHUS, treatment
should be changed to eculizumab, as long-term plasma ther-
apy has not been shown to change the devastating course of
aHUS.1,5,9,10 In our patient, plasma exchanges were performed
initially, achieving control of haemolytic activity; once the
diagnosis of aHUS was established, treatment was changed toro E, Ocampo-Kohn C, Aristizabal-Alzate A, Zuluaga-Quintero M,
mpromiso renal, neurológico, ocular y cardiovascular.
for plasma exchange and no further relapses (Fig. 1). However,
the patient was left with the sequela of ESRD.
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Table 1 – Laboratory results.
Urine
cytochemistry
Appearance pH Density Proteinuria Red blood cells Leucocytes Proteinuria
Turbid 8 1.015 >300 mg/dL >50/HPF 21–50/HPF 850 mg/day
Capillary gases pH  HCO3 PCO2 PO2 PaO2/FiO2 Lactate Base excess
7.24 9.6 mmol/L 22 mmHg 121 mmHg 242 1.3 mmol −15.7 mmol/L
Renal and
metabolic proﬁle
Creatinine BUN Uric acid Sodium Potassium Chloride Phosphorus
19.7 mg/dL 128 mg/dL 8.5 mg/dL 140 mEq/L 4.2 mEq/L 100 mEq/L 8 mg/dL
Corrected
calcium
Ionised calcium Magnesium Albumin Glucose Total cholesterol HDL-cholesterol
6.7 mg/dl 0.65 mmol/L 1.53 mg/dL 2.8 g/dL 92 mg/dL 108 mg/dL 31 mg/dL
LDL-cholesterol Triglycerides Vitamin D PTH Vitamin B12 Ferritin Folic acid
63.6 mg/dL 61 mg/dL 19.3 ng/mL 751 pg/mL 286 pg/mL 551 ng/mL 7.7 ng/mL
Haematological
proﬁle
Haemoglobin Haematocrit Leucocytes Neutrophils Lymphocytes Monocytes Basophils
5.1 g/dL 14% 6.200 mm3 80.2% 11.3% 8.1% 0.4%
Eosinophils Platelets Corrected
reticulocytes
PBF LDH Haptoglobin ADAMTS13 activity
0% 82,000 mm−3 5.2% Schistocytes ++ 547 U/L 10.6 mg/dL 74.5%
PTT PTT control PT INR Fibrinogen
30 s 26.1 11.3 s 1.04 435 mg/dL
Liver proﬁle TB  DB IB AST ALT ALP
1.5 mg/dL 0.4 mg/dL 1.1 mg/dL 22 U/L 18 U/L 77 U/L
Immunological
studies
C3 C4 ANA ENA MPOAb PR3Ab Direct Coombs
106 mg/dL 28.8 mg/dL Negative Negative Negative Negative Negative
Complement genetic study No pathological mutations were found for: ADAMTS13, C3, CD46, CFB, CFH, CFHR1, CFHR2, CFHR3, CFHR4, CFHR5, CFI, DGKE, PIGA, THBD
Other
investigations
Protein electrophoresis HIV Hepatitis B Hepatitis C VDRL Renal biopsy
Hypoalbuminemia, non-speciﬁc
elevation of alpha 1 band and B2
Negative Negative Negative Negative Thrombotic
microangiopathy
Plain CT head Echocardiography Renal ultrasound
Normal Pulmonary hypertension and mild
pericardial effusion
Small  echogenic kidneys with loss of corticomedullary
differentiation
ALP, alkaline phosphatase; ALT, alanine aminotransferase; ANA, antinuclear antibodies; AST, aspartate aminotransferase; BUN, blood urea nitrogen; C3, complement C3; C4, complement C4; CT,
computed tomography; DB, direct bilirubin; ENA, antibodies against the extractable nuclear antigens anti-RNP, -Sm, -Ro, and -La; HCO3, serum bicarbonate; HDL cholesterol, high-density lipoprotein
cholesterol; HIV, human immunodeﬁciency virus antibody; HPF, high-power ﬁeld; IB, indirect bilirubin; LDH, lactate dehydrogenase; LDL cholesterol, low-density lipoprotein cholesterol; MPOAb,
anti-myeloperoxidase antibodies; PBF, peripheral blood ﬁlm; PCO2, partial pressure of carbon dioxide; PO2, partial pressure of oxygen; PR3Ab, anti-proteinase 3 antibodies; PTH, parathyroid hormone;
TB, total bilirubin; VDRL, non-treponemal test for syphilis.
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Fig. 1 – Results of laboratory investigations during treatment.
Laboratory parameters during treatment: 13 sessions of plasma 
arrow); eculizumab, started on 29 September 2014 (green arrow).
values are at a scale of 1 × 104.
Conclusion
Atypical HUS is a rare genetic disease that affects children
and adults, characterised by the presence of non-immune
microangiopathic haemolytic anaemia, thrombocytopenia
and multi-organ damage. The clinical course can be devas-
tating and endanger patients’ life and quality of life, leaving
them with severe sequelae such as ESRD. Treatment with
eculizumab must be started early to halt multi-organ damage
and avoid death.
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n unusual  case  of  peritonitis
n peritoneal  dialysis
n  caso  infrecuente  de  peritonitis  
n  diálisis  peritoneal
ear Editor,
ontinuous ambulatory peritoneal dialysis (CAPD) is used as
n alternative to hemodialysis and has very few complica-
ions which include abdominal hernia, peritonitis, processus
aginalis, pleural leakage, and those related to the catheter
xit site.1 It may occasionally be complicated by leakage of
ialysate ﬂuid into the abnormal sites.2,3 We report a case of
 woman who  experienced vaginal leakage during CAPD and
fter peritonitis.
A 24 year old female patient was diagnosed with end stage
enal disease during pregnancy. There was no other etio-
ogical factor, but hypertension. Patient was recommended
0 hours of hemodialysis, but she refused and gave birth to
 living child on the 38th gestational week. She has been
n CAPD for the last 3 months. Since last week she has
tarted to have abdominal pain accompanied with nausea
nd fever (>38 ◦C). With these complaints she was referred
o our policlinic and her peritoneal ﬂuid cell count was
ound 4860/mm3 (95% polymorphonuclear leukocytes). Cul-
ures were obtained and she was admitted to our hospital
ith the diagnosis of peritonitis. Blood analysis showed leu-
ocytes 9000/mm3, hemoglobin: 8.8 g/dl (11.5–16), C-reactive
rotein: 14.2 mg/dl (0–0.5), sedimentation: 135 mm/hour. Pseu-
omonas aeruginosa was detected in blood cultures. She was
n empiric ceftazidime and cefazolin treatment and treat-
ent was continued because P. aeruginosa was found sensitive
o this treatment. Urine culture remained sterile. Patient
tated that there is dialysate in her vagina. She was con-
ulted with obstetrics and gynecology regarding any ﬁstulas.
 urine catheter was placed and it is understood that ori-
in of dialysate was vagina. Contrast enhanced computerized
omography was done showing a vaginal ﬁstula (Figs. 1 and 2).
APD catheter was removed. Surgical operation was found
nnecessary and hemodialysis was started. Patient was dis-
harged after 3 weeks of ant biotherapy.
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